Descrizione

Human genetics is the scientific study of inherited human variation. Understanding genetic factors and genetic disorders is important in learning more about promoting health and preventing disease. Some genetic changes have been associated with an increased risk of having a child with a birth defect or developmental disability or developing diseases such as cancer or heart disease. According to a report by StrategyHelix, the global human genetics market is set to increase by US$ 51.5 miliardi durante 2022-2028, growing at a CAGR of 15.3% durante il periodo di previsione.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2018-2021 e previsione a 2028 covering key market aspects like sales value for human genetics. The global human genetics market is segmented on the basis of application, test method, e regione. On the basis of application, the global human genetics market has been segmented into diagnostic & treatment, preventive medicine, altri. Tra questi, the diagnostic & treatment segment was accounted for the highest revenue generator in 2021. By test method, the global human genetics market has been segmented into carrier testing, karyotyping, next-generation sequencing (NGS), noninvasive prenatal testing (NIPT), pharmacogenomic testing, SEPT9 biomarker testing, thrombophilia testing, altri. Geograficamente, the global human genetics market is segmented into Asia Pacific, Europa, Nord America, Rest of the World (RoW).

The global human genetics market is highly competitive. Key companies profiled in the report include Atrys Health S.A., Bode Cellmark Forensics Inc., Elabscience Biotechnology Inc., EUROFINS MEGALAB S.A., FULLGENOMICS S.L., GENinCode Plc, Genologica, LABORATORIO ECHEVARNE S.A., Myriad Genetics Inc., NIMGENETICS GENOMICA Y MEDICINA S.L., Sistemas Genomicos S.L., SYNLAB International GmbH.

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the human genetics market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Applicazione: diagnostic & treatment, preventive medicine, altri
Test method: carrier testing, karyotyping, next-generation sequencing (NGS), noninvasive prenatal testing (NIPT), pharmacogenomic testing, SEPT9 biomarker testing, thrombophilia testing, altri
Regione: Asia Pacifico, Europa, Nord America, Rest of the World (RoW)
Anni considerati: la presente relazione copre il periodo 2018 A 2028

Principali vantaggi per gli stakeholder

– Get a comprehensive picture of the global human genetics market
– Individuare i settori in crescita e le tendenze per gli investimenti

Sommario

Parte 1. introduzione
– Ambito dello studio
– Periodo di studio
– Ambito geografico
– Metodologia di ricerca
Parte 2. Human genetics market overview
Parte 3. Market breakdown by application
– Diagnostic & treatment
– Preventive medicine
– Altri
Parte 4. Market breakdown by test method
– Carrier testing
– Karyotyping
– Next-generation sequencing (NGS)
– Noninvasive prenatal testing (NIPT)
– Pharmacogenomic testing
– SEPT9 biomarker testing
– Thrombophilia testing
– Altri
Parte 5. Market breakdown by region
– Asia Pacifico
– Europa
– Nord America
– Rest of the World (RoW)
Parte 6. Aziende chiave
– Atrys Health, SA.
– Bode Cellmark Forensics, Inc.
– Elabscience Biotechnology Inc.
– EUROFINS MEGALAB S.A.
– FULLGENOMICS, S.L.
– GENinCode Plc
– Genologica
– LABORATORIO ECHEVARNE S.A.
– Myriad Genetics, Inc.
– NIMGENETICS GENOMICA Y MEDICINA, S.L.
– Sistemas Genomicos, S.L.
– SYNLAB International GmbH
Informazioni su StrategyHelix
Disclaimer